chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Erythema, Feeling hot, Paraesthesia, Pruritus, Rash erythematous
Clinical narrative: "My" neck began to itch, "I" rubbed it with "my" hands for a few minutes and then it started to tingle; "I"  went to look in the mirror and noticed that "my" neck and "my" face, were red.; "I" then began to feel a warm sensation on "my" arms and legs/ The warm, rushing sensation in "my" extremities lasted for about 5 minutes.; upon looking at them, "I" noticed red rashes around "my" elbows and knees/Around 2 hours later, the rashes were completely gone.; "My" neck began to itch, "I" rubbed it with "my" hands for a few minutes and then it started to tingle; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the right arm on 16Apr2021 at 09:15 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. The medical history included fibromyalgia, anxiety, panic disorder, depression, kidney stones, allergy to nickel which caused dermatitis and allergy to contrast dye which caused anaphylaxis. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included escitalopram (MANUFACTURER UNKNOWN), vitamin b complex (VITAMIN B), ascorbic acid (VITAMIN C), vitamin d nos (VITAMIN D) and probiotic (unspecified); all for unknown indications from unknown dates and unknown if ongoing. On 20Apr2021, around 11:10, the patient's neck began to itch, she rubbed it with her hands for a few minutes and at 11:15, it started to tingle, she went to look in the mirror and noticed that her neck and her face were red. The patient then began to feel a warm sensation on her arms and legs and upon looked at them, she noticed red rashes around her elbows and knees. The warm, rushing sensation in her extremities lasted for about 5 minutes. The rashes were began to subside at that point. Around 2 hours later, the rashes were completely gone. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events neck began to itch, then it started to tingle, neck and face were red was unknown, while the clinical outcome of the event felt a warm sensation on arms and legs was resolved on 20Apr2021 at 11:20 and red rashes around elbows and knees was resolved on 20Apr2021.    No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Rash
Clinical narrative: Rashes on left and right arms; Vaccination Dose 1 on 31Mar2021 and Dose 2 on 08Apr2021 before 19 days; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 08Apr2021 at 16:15 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and undifferentiated connective tissue disease. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine sodium (SYNTHROID), hydroxychloroquine (PLAQUENIL), ibuprofen (ADVIL), Centrum (MANUFACTURER UNKNOWN), Gabap (MANUFACTURER UNKNOWN) and levocetirizine dihydrochloride (XYZAL); all for unknown indications from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 31Mar2021 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. On 13Apr2021 at 00:00, the patient experienced rashes on left and right arms. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event rashes on left and right arms was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Inappropriate schedule of product administration, Rash
Clinical narrative: Rashes on left and right arms; Vaccination Dose 1 on 31Mar2021 and Dose 2 on 08Apr2021 before 19 days; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 08Apr2021 at 16:15 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and undifferentiated connective tissue disease. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine sodium (SYNTHROID), hydroxychloroquine (PLAQUENIL), ibuprofen (ADVIL), Centrum (MANUFACTURER UNKNOWN), Gabap (MANUFACTURER UNKNOWN) and levocetirizine dihydrochloride (XYZAL); all for unknown indications from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 31Mar2021 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. On 13Apr2021 at 00:00, the patient experienced rashes on left and right arms. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event rashes on left and right arms was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Disorientation, Dizziness, Fatigue, Headache, Injection site pain
Clinical narrative: Vertigo (dizziness); Vertigo (dizziness); Injection site soreness; Fatigue; Mild fever; Headache; Vertigo (dizziness and disorientation); This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 07Apr2021 at 10:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included endometrial hyperplasia. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included norethisterone (NORETHINDRONE), taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 17Mar2021 at 11:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. On 07Apr2021, after the second dose of vaccination, the patient had typical side effects, injection site soreness, fatigue, mild fever and headache that lasted 24 to 48 hours. On 08Apr2021, about 16 hours after the vaccination (in the middle of the night), the patient experienced an unexpected side effect vertigo (dizziness). The patient had continued to experience vertigo (dizziness and disorientation) since then till 14 days at the time of this report and had visited her doctor to address this ongoing issue. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with unspecified allergy medications and vestibular exercises. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events injection site soreness, fatigue, mild fever and headache was resolved on an unknown date in Apr2021 while that of vertigo (dizziness and disorientation) was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Sleep disorder, Vertigo
Clinical narrative: Vertigo (dizziness); Vertigo (dizziness); Injection site soreness; Fatigue; Mild fever; Headache; Vertigo (dizziness and disorientation); This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 07Apr2021 at 10:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included endometrial hyperplasia. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included norethisterone (NORETHINDRONE), taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 17Mar2021 at 11:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. On 07Apr2021, after the second dose of vaccination, the patient had typical side effects, injection site soreness, fatigue, mild fever and headache that lasted 24 to 48 hours. On 08Apr2021, about 16 hours after the vaccination (in the middle of the night), the patient experienced an unexpected side effect vertigo (dizziness). The patient had continued to experience vertigo (dizziness and disorientation) since then till 14 days at the time of this report and had visited her doctor to address this ongoing issue. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with unspecified allergy medications and vestibular exercises. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events injection site soreness, fatigue, mild fever and headache was resolved on an unknown date in Apr2021 while that of vertigo (dizziness and disorientation) was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Disorientation, Dizziness, Fatigue, Headache, Pyrexia
Clinical narrative: Vertigo (dizziness); Vertigo (dizziness); Injection site soreness; Fatigue; Mild fever; Headache; Vertigo (dizziness and disorientation); This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 07Apr2021 at 10:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included endometrial hyperplasia. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included norethisterone (NORETHINDRONE), taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 17Mar2021 at 11:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. On 07Apr2021, after the second dose of vaccination, the patient had typical side effects, injection site soreness, fatigue, mild fever and headache that lasted 24 to 48 hours. On 08Apr2021, about 16 hours after the vaccination (in the middle of the night), the patient experienced an unexpected side effect vertigo (dizziness). The patient had continued to experience vertigo (dizziness and disorientation) since then till 14 days at the time of this report and had visited her doctor to address this ongoing issue. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with unspecified allergy medications and vestibular exercises. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events injection site soreness, fatigue, mild fever and headache was resolved on an unknown date in Apr2021 while that of vertigo (dizziness and disorientation) was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vaccination site pain, Vertigo
Clinical narrative: Vertigo (dizziness); Vertigo (dizziness); Injection site soreness; Fatigue; Mild fever; Headache; Vertigo (dizziness and disorientation); This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 07Apr2021 at 10:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included endometrial hyperplasia. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included norethisterone (NORETHINDRONE), taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 17Mar2021 at 11:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. On 07Apr2021, after the second dose of vaccination, the patient had typical side effects, injection site soreness, fatigue, mild fever and headache that lasted 24 to 48 hours. On 08Apr2021, about 16 hours after the vaccination (in the middle of the night), the patient experienced an unexpected side effect vertigo (dizziness). The patient had continued to experience vertigo (dizziness and disorientation) since then till 14 days at the time of this report and had visited her doctor to address this ongoing issue. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with unspecified allergy medications and vestibular exercises. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events injection site soreness, fatigue, mild fever and headache was resolved on an unknown date in Apr2021 while that of vertigo (dizziness and disorientation) was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Rash papular
Clinical narrative: LEFT arm broke out in blistery rash from left wrist to left shoulder; All side effects were in left arm (joint + muscle pain) plus this rash; All side effects were in left arm (joint + muscle pain) plus this rash; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 16Apr2021 at 09:45 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and high cholesterol. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had received injection in right arm due to being left handed. On 18Apr2021, his left arm broke out in blistery rash from left wrist to left shoulder. All side effects were in left arm including joint and muscle pain plus the rash. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events left arm broke out in blistery rash from left wrist to left shoulder; all side effects were in left arm including joint and muscle pain plus the rash was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Myalgia, Rash vesicular
Clinical narrative: LEFT arm broke out in blistery rash from left wrist to left shoulder; All side effects were in left arm (joint + muscle pain) plus this rash; All side effects were in left arm (joint + muscle pain) plus this rash; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 16Apr2021 at 09:45 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and high cholesterol. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had received injection in right arm due to being left handed. On 18Apr2021, his left arm broke out in blistery rash from left wrist to left shoulder. All side effects were in left arm including joint and muscle pain plus the rash. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events left arm broke out in blistery rash from left wrist to left shoulder; all side effects were in left arm including joint and muscle pain plus the rash was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood pressure decreased, Dizziness, Fatigue
Clinical narrative: blood pressure was 83/50; had been feeling achy/tired; had been feeling achy/tired; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 19Apr2021 at 10:30 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic fatigue.  The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included cannabidiol (MEDTERRA CBD) started on an unknown date, for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks, prior to the vaccination. On 20Apr2021 at 13:15, the day after the vaccine when the patient was at the doctor for an eye appointment, they had done a routine blood pressure check. The patient had been feeling achy/tired and her blood pressure was 83/50. It was usually around 125/80. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. On an unknown date, the patient underwent blood pressure check and the result was 125/80 (unspecified units) and on 20Apr2021, the blood pressure check result was 83/50 (unspecified units). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events blood pressure was 83/50, had been feeling achy/tired was recovered on unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood pressure measurement, Fatigue, Hypotension, Pain
Clinical narrative: blood pressure was 83/50; had been feeling achy/tired; had been feeling achy/tired; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 19Apr2021 at 10:30 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic fatigue.  The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included cannabidiol (MEDTERRA CBD) started on an unknown date, for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks, prior to the vaccination. On 20Apr2021 at 13:15, the day after the vaccine when the patient was at the doctor for an eye appointment, they had done a routine blood pressure check. The patient had been feeling achy/tired and her blood pressure was 83/50. It was usually around 125/80. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. On an unknown date, the patient underwent blood pressure check and the result was 125/80 (unspecified units) and on 20Apr2021, the blood pressure check result was 83/50 (unspecified units). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events blood pressure was 83/50, had been feeling achy/tired was recovered on unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lymphadenopathy, Pain, Sinus congestion, Upper respiratory tract congestion
Clinical narrative: Body aches; Joint pain; Lymph node swelling under left arm and across left breast; Head and chest congestion; Head and chest congestion; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9266) via an unspecified route of administration in the left arm on 16Feb2021 at 13:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The medical history included diabetes, high blood pressure and high cholesterol. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to vaccination. The patient received unspecified concomitant medications. The patient previously received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9262) via an unspecified route of administration in the left arm on 26Jan2021 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient also took previously acetylsalicylic acid (ASPIRIN) and experienced allergy. On 17Feb2021 at 14:00, the patient experienced body aches, joint pain, lymph node swelling under left arm and across left breast and head and chest congestion. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events body aches, joint pain, lymph node swelling under left arm and across left breast and head and chest congestion were resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Lymphadenopathy, Pain, Respiratory tract congestion, Upper respiratory tract congestion
Clinical narrative: Body aches; Joint pain; Lymph node swelling under left arm and across left breast; Head and chest congestion; Head and chest congestion; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9266) via an unspecified route of administration in the left arm on 16Feb2021 at 13:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The medical history included diabetes, high blood pressure and high cholesterol. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to vaccination. The patient received unspecified concomitant medications. The patient previously received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9262) via an unspecified route of administration in the left arm on 26Jan2021 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient also took previously acetylsalicylic acid (ASPIRIN) and experienced allergy. On 17Feb2021 at 14:00, the patient experienced body aches, joint pain, lymph node swelling under left arm and across left breast and head and chest congestion. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events body aches, joint pain, lymph node swelling under left arm and across left breast and head and chest congestion were resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus; it is constant noise in head; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8729) via an unspecified route of administration in the left arm on 15Apr2021 at 15:15 (at the age of 55-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroid, migraine and benign positional vertigo. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), vitamin D not otherwise specified (MANUFACTURER UNKNOWN), multivitamins (MANUFACTURER UNKNOWN) and ibuprofen (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. On 18Apr2021, the patient experienced tinnitus; it was constant noise in head and had no pain. No therapeutic measures were taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event tinnitus; it was constant noise in head was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Bone pain, Headache, Myalgia, Nausea, Pyrexia
Clinical narrative: Headache; All over bone/muscle aches; All over bone/muscle aches; Nausea; Vomiting; High blood pressure; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the right arm on 19Apr2021 at 10:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome (IBS), high blood pressure, high cholesterol, and sulfonamide allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had received other medication which was not specified within two weeks of vaccination for unknown indication on unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 29Mar2021 at 10:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient previously took sulfur (MANUFACTURER UNKNOWN) and experienced drug allergy known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021 at 03:00, the patient experienced headache, all over bone and muscle aches, nausea, vomiting, high blood pressure. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, all over bone and muscle aches, nausea, vomiting, high blood pressure was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Vomiting
Clinical narrative: Headache; All over bone/muscle aches; All over bone/muscle aches; Nausea; Vomiting; High blood pressure; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the right arm on 19Apr2021 at 10:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome (IBS), high blood pressure, high cholesterol, and sulfonamide allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had received other medication which was not specified within two weeks of vaccination for unknown indication on unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 29Mar2021 at 10:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient previously took sulfur (MANUFACTURER UNKNOWN) and experienced drug allergy known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021 at 03:00, the patient experienced headache, all over bone and muscle aches, nausea, vomiting, high blood pressure. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, all over bone and muscle aches, nausea, vomiting, high blood pressure was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood pressure measurement, Bone pain, Headache, Hypertension, Myalgia
Clinical narrative: Headache; All over bone/muscle aches; All over bone/muscle aches; Nausea; Vomiting; High blood pressure; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the right arm on 19Apr2021 at 10:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome (IBS), high blood pressure, high cholesterol, and sulfonamide allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had received other medication which was not specified within two weeks of vaccination for unknown indication on unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 29Mar2021 at 10:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient previously took sulfur (MANUFACTURER UNKNOWN) and experienced drug allergy known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021 at 03:00, the patient experienced headache, all over bone and muscle aches, nausea, vomiting, high blood pressure. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, all over bone and muscle aches, nausea, vomiting, high blood pressure was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Nausea, Vomiting
Clinical narrative: Headache; All over bone/muscle aches; All over bone/muscle aches; Nausea; Vomiting; High blood pressure; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the right arm on 19Apr2021 at 10:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome (IBS), high blood pressure, high cholesterol, and sulfonamide allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had received other medication which was not specified within two weeks of vaccination for unknown indication on unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 29Mar2021 at 10:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient previously took sulfur (MANUFACTURER UNKNOWN) and experienced drug allergy known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021 at 03:00, the patient experienced headache, all over bone and muscle aches, nausea, vomiting, high blood pressure. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, all over bone and muscle aches, nausea, vomiting, high blood pressure was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: 72 hours after receiving dose, I woke up to extremely loud tinnitus; unable to sleep; Persistent random joint and muscle pain has been present since 18 hours post-dose.; Persistent random joint and muscle pain has been present since 18 hours post-dose.; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 14Apr2021 at 15:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 03Mar2021 at 17:45 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. On 15Apr2021 at 09:30, 18 hours post-dose, the patient had persistent random joint and muscle pain. On 17Apr2021 at 15:30, 72 hours after receiving dose, the patient woke up to extremely loud tinnitus, unable to sleep and tinnitus had been constant ever since. On 19Apr2021, the patient underwent RT PCR test and the result was Negative. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events persistent random joint and muscle pain, woke up to extremely loud tinnitus and unable to sleep was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Insomnia, Myalgia, SARS-CoV-2 test, Tinnitus
Clinical narrative: 72 hours after receiving dose, I woke up to extremely loud tinnitus; unable to sleep; Persistent random joint and muscle pain has been present since 18 hours post-dose.; Persistent random joint and muscle pain has been present since 18 hours post-dose.; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 14Apr2021 at 15:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 03Mar2021 at 17:45 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. On 15Apr2021 at 09:30, 18 hours post-dose, the patient had persistent random joint and muscle pain. On 17Apr2021 at 15:30, 72 hours after receiving dose, the patient woke up to extremely loud tinnitus, unable to sleep and tinnitus had been constant ever since. On 19Apr2021, the patient underwent RT PCR test and the result was Negative. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events persistent random joint and muscle pain, woke up to extremely loud tinnitus and unable to sleep was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood pressure increased, Euphoric mood, Heart rate increased, Paraesthesia
Clinical narrative: Fast heart rate; High blood pressure; Tingling; High/buzzed feeling; High/buzzed feeling; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 21Apr2021 at 14:00 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included Ehlers-Danlos syndrome, allergy to penicillin and allergy to bee stings (allergy to insect sting) and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. On 21Apr2021 at 18:00, the patient experienced fast heart rate, high blood pressure, tingling and high or buzzed feeling. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events fast heart rate, high blood pressure, tingling and high or buzzed feeling was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Euphoric mood, Feeling drunk, Heart rate increased, Hypertension, Paraesthesia
Clinical narrative: Fast heart rate; High blood pressure; Tingling; High/buzzed feeling; High/buzzed feeling; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 21Apr2021 at 14:00 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included Ehlers-Danlos syndrome, allergy to penicillin and allergy to bee stings (allergy to insect sting) and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. On 21Apr2021 at 18:00, the patient experienced fast heart rate, high blood pressure, tingling and high or buzzed feeling. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events fast heart rate, high blood pressure, tingling and high or buzzed feeling was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Dysmenorrhoea, Headache, Heavy menstrual bleeding, Hot flush
Clinical narrative: Temperature fluctuations (fluctuating fairly quickly with multiple degree differences within minutes of each other); Severe nausea worsening at nigh; Menstruation bleeding was heavier than normal; Severe cramps; Migraines; Chills; Hot flashes; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 01Apr2021 at 08:15 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, scoliosis, generalized anxiety. The patient was allergic to dairy and bird dandruff. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included vitamin d (MANUFACTURER UNKNOWN) and women's multivitamin (MANUFACTURER UNKNOWN); both for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 12Apr2021 starting at 17:00 (estimated), the patient experienced chills and hot flashes and continuing until 18Apr2021. No temperature measured except the 16Apr2021 when temperature fluctuations measured between 94-98 degrees Fahrenheit throughout the day (fluctuating fairly quickly with multiple degree differences within minutes of each other, thermometer was correct when compared with a second thermometer's readings). On 13Apr2021 (reported as tuesday), the patient had migraines all the day. On 14Apr2021 (reported as wednesday) with severe nausea worsening at night, stayed laying or sitting down to keep from throwing up. Period (menstruation) started this day as well, and bleeding was heavier than normal with severe cramps which she never experienced. Migraines are also never experienced as a symptom of menstruation. Migraines continued until Monday 19Apr2021 but were much lighter and without nausea or stomach cramping. Period ended on 21Apr2021 (reported as today), the blood having been heavy the entire time. The patient reported that she was still getting headaches but nothing was as severe. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  On 16Apr2021, the patient underwent Body temperature test and the result was found to be 94-98 degrees Fahrenheit. The clinical outcome of the events chills and hot flashes was resolved on 18Apr2021.The clinical outcome of the events temperature fluctuations, severe nausea worsening at night and stomach cramping was resolved on an unknown date in Apr2021. The clinical outcome of the events menstruation bleeding was heavier than normal was resolved on 21Apr2021; while that of the event migraines was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.